secwatch.observer — SEC 8-K summary
======================================

Issuer:     Alector, Inc. (ALEC)
CIK:        0001653087
Form:       8-K
Filed at:   2025-08-07T23:59:59+00:00
Accession:  0000950170-25-105023
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Alector Q2 net loss $30.5M; cash $307.3M; Phase 3 latozinemab data mid-Q4
-------------------------------------------------------------------------

- Net loss $30.5M ($0.30/sh) vs $38.7M ($0.40/sh) in Q2 2024; revenue $7.9M down from $15.1M.
- Cash, cash equivalents, and investments $307.3M, providing runway into H2 2027.
- On track to report topline data from INFRONT-3 Phase 3 trial of latozinemab in FTD-GRN by mid-Q4 2025.
- Guidance updated: collaboration revenue $13-18M, R&D expenses $130-140M, G&A $55-65M for FY2025.
- Neil Berkley appointed interim CFO; USPTO issued patent for latozinemab treatment method.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1653087/000095017025105023/0000950170-25-105023-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1653087/000095017025105023/alec-20250807.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-105023

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer